Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has

Eikon Therapeutics，这家由曾带领癌症药物Keytruda获得FDA批准的前默克高管领导的公司，已经

raised $350.7 million

筹集了3.507亿美元

to support a pipeline that includes a lead drug candidate now in a pivotal test that could support expanding melanoma treatment to a pair of new immunotherapy targets.

支持一条管道，其中包括一个主要的药物候选物，目前正处于关键测试阶段，这可能支持将黑色素瘤治疗扩展到一对新的免疫治疗靶点。

The lead Eikon drug, EIK1001, is a small molecule designed to hit toll-like receptors 7 and 8 (TLR7/8). Activating these receptors is intended to spark an immune response that fights cancer. According to

Eikon公司的主要药物EIK1001是一种小分子，旨在靶向Toll样受体7和8（TLR7/8）。激活这些受体旨在激发对抗癌症的免疫反应。根据

clinical trial records

临床试验记录

, the Phase 3 test is evaluating EIK1001 alongside Merck’s checkpoint inhibitor Keytruda, comparing that combination against Keytruda and a placebo as a first-line treatment for advanced melanoma. The trial’s targeted enrollment is 740 patients. Separately, the

，第三阶段试验正在评估EIK1001与默克的检查点抑制剂Keytruda的联合使用，将该组合与Keytruda和安慰剂进行比较，作为晚期黑色素瘤的一线治疗。该试验的目标入组人数为740名患者。另外，

Eikon pipeline

Eikon 管道

lists EIK1001 in Phase 2 testing in non-small cell lung cancer.

列出EIK1001在非小细胞肺癌的第二阶段测试。

EIK1001 was initially developed by Seven and Eight Biopharmaceuticals. Eikon

EIK1001 最初由 Seven and Eight Biopharmaceuticals 开发。Eikon

licensed global rights

全球授权权利

to that immunotherapy and another TLR7/8 agonist in 2023; financial terms were not disclosed.

对这种免疫疗法和另一种TLR7/8激动剂的交易发生在2023年；财务条款未披露。

Sponsored Post

赞助帖子

The Funding Model for Cancer Innovation is Broken — We Can Fix It

癌症创新的资金模式已崩溃——我们可以修复它

Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.

缩小癌症健康公平差距需要通过新的资金投入方式实现医学突破。

By Eve McDavid - CEO of Mission-Driven Tech

作者：伊芙·麦克戴维 - 使命驱动科技公司首席执行官

Eikon is also in the clinic with EIK1003, an inhibitor of PARP1. This enzyme is key to DNA repair in cells, so blocking it leads to cell death. Though PARP inhibitors are already approved to treat certain cancers, they come with toxicity risks thought to be associated with the blocking of PARP2. Eikon’s EIK1003 selectively inhibits PARP1 with the goal of offering the same efficacy as currently available PARP inhibitors while avoiding the toxicity of those drugs..

Eikon公司还有另一款PARP1抑制剂EIK1003也已进入临床阶段。PARP1这种酶是细胞DNA修复的关键，因此阻断它会导致细胞死亡。尽管PARP抑制剂已经被批准用于治疗某些癌症，但它们带来了被认为与阻断PARP2有关的毒性风险。Eikon公司的EIK1003能够选择性地抑制PARP1，目标是在提供与现有PARP抑制剂相同疗效的同时，避免这些药物的毒性。

EIK1003 is in Phase 1 testing in patients with breast, ovarian, prostate, or pancreatic cancers. Eikon is also taking a PARP1-selective approach with EIK1004, which is designed to penetrate the blood-brain barrier to treat brain cancers. The company’s website states that a Phase 1 test of this drug began in the first quarter of this year..

EIK1003正在乳腺癌、卵巢癌、前列腺癌或胰腺癌患者中进行第一阶段测试。Eikon还采用了一种PARP1选择性方法，使用EIK1004，该药物旨在穿透血脑屏障以治疗脑癌。该公司网站称，这种药物的第一阶段测试在今年第一季度开始。

“With clinical studies now operating in 28 countries, across five continents, we are accelerating the development of much-needed therapies while continuing to expand our research and development capabilities,” CEO Roger Perlmutter said in a prepared statement.

“随着目前在五大洲、28个国家开展的临床研究，我们正在加速开发急需的疗法，同时继续扩展我们的研发能力，”首席执行官罗杰·珀尔穆特在一份准备好的声明中表示。

Eikon’s PARP inhibitors came from Impact Therapeutics. The company’s pipeline also includes assets acquired from Cleave Therapeutics in preclinical development for cancer and neurodegenerative disease. Financial terms for

Eikon的PARP抑制剂来自Impact Therapeutics。该公司研发管线还包括从Cleave Therapeutics收购的处于癌症和神经退行性疾病临床前开发阶段的资产。财务条款尚未披露。

these deals

这些交易

were not disclosed.

未被披露。

Sponsored Post

赞助帖子

Tips for Greater Healthcare Practice Success in 2025

2025年医疗实践成功的更多技巧

Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.

加入我们，于东部时间2月26日下午3点，我们将深入探讨实践中损失时间和金钱的关键领域，并提供克服这些问题的解决方案。

By Elation Health and MedCity News

由Elation Health和MedCity News提供

Hayward, California-based

加利福尼亚州海沃德的

Eikon emerged in 2021, backed by $148 million in funding

Eikon于2021年成立，获得了1.48亿美元的资助。

led by The Column Group. Perlmutter, formerly the president of Merck Research Laboratories, was named the startup’s CEO. Eikon discovers drugs with proprietary technology that visualizes proteins, enabling scientists to see how they move within a live cell in real time. This visualization technology is based on the research of company co-founder Eric Betzig, who was awarded the .

由The Column Group领投。Perlmutter曾是默克研究实验室的总裁，被任命为这家初创公司的首席执行官。Eikon利用专有技术发现药物，该技术能够可视化蛋白质，使科学家能够实时观察它们在活细胞中的运动。这种可视化技术基于公司联合创始人Eric Betzig的研究，他因此获得了奖项。

2014 Nobel Prize in Chemistry

2014年诺贝尔化学奖

.

。

The most advanced internally discovered Eikon drug candidate is EIK1005. This drug is an inhibitor of WRN, an enzyme that plays a role in DNA damage repair. WRN has emerged as a therapeutic target for tumors characterized by high microsatellite instability (MSI) and it’s a driver of certain gastrointestinal and endometrial cancers.

最先进的内部发现的Eikon候选药物是EIK1005。该药物是一种WRN酶的抑制剂，WRN在DNA损伤修复中起作用。WRN已成为具有高微卫星不稳定性（MSI）特征的肿瘤的治疗靶点，并且是某些胃肠道和子宫内膜癌的驱动因素。

According to Eikon’s website, the company is developing EIK1005 for MSI-high cancers and sensitive cancers that have defects in DNA repair. The company expects to begin a Phase 1 test of EIK1005 in the first half of this year..

根据Eikon的网站，该公司正在开发EIK1005，用于MSI高的癌症和DNA修复有缺陷的敏感癌症。该公司预计将在今年上半年开始EIK1005的1期试验。

Eikon’s last financing was in 2023, disclosed as $106 million raised in the first tranche of a

Eikon上次融资是在2023年，披露的第一批资金为1.06亿美元。

Series C round

C轮融资

. With the new financing announced Wednesday, the company said it has raised about $1.1 billion to date. The latest round was led by earlier investors in the company who were joined by some new investors. This investment syndicate includes Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T.

周三宣布的新一轮融资使该公司迄今为止筹集的资金总额达到约11亿美元。此轮融资由公司早期投资者领投，同时加入了一些新的投资者。该投资集团包括Lux Capital、Alexandria Venture Investments、AME Cloud Ventures、The Column Group、E15 VC、Foresite Capital、General Catalyst、Soros Capital、StepStone Group，以及由T.管理的基金和账户。

Rowe Price Associates and UC Investments..

罗威价格协会和加州大学投资公司。

Public domain image by Julio C. Valencia via the

公共领域图片，由胡里奥·C·巴伦西亚通过

National Cancer Institute

国家癌症研究所